Description
Adisord Pharmacodynamics
Nifuroxazide is a nitrofuran derivative with antimicrobial activity against Gram-positive Staphylococcus spp. and some Gram-negative microorganisms: Yersinia spp., Escherichia spp., Citrobacter spp., Enterobacter spp., Salmonella spp. Nifuroxazide has no antimicrobial effect against Proteus vulgaris, Klebsiella spp., Proteus mirabilis and Pseudomonas aeruginosa. Supposedly blocks the activity of dehydrogenases and inhibits respiratory chains, tricarboxylic acid cycle and a number of other biochemical processes in the microbial cell. It does not disturb the balance of intestinal microflora. In acute bacterial diarrhea restores intestinal eubiosis. In case of infection with enterotropic viruses prevents the development of bacterial superinfection
Indications
Diarrhea of bacterial genesis without signs of helminth infestation.
Contraindications
-Hypersensitivity to nifuroxazide, nitrofuran derivatives or any excipients of the drug
-Childhood age under 3 years old.
Usage during pregnancy and lactation
Preclinical studies have shown no risk to the fetus, but there are no controlled studies in pregnant women/.
Potential risk to humans is unknown. Breastfeeding is possible with short-term therapy. During pregnancy and during breastfeeding, use only if the estimated benefit to the mother exceeds the potential risk to the fetus and child. It is necessary to consult a physician.
Dosage and administration
- Used orally. The capsule should be swallowed in whole with a small amount of water.
Adults and children over 6 years of age: 2 capsules of 100 mg or 1 capsule of 200 mg four times a day (800 mg/day). - Children 3 to 6 years of age: 2 capsules of 100 mg or 1 capsule of 200 mg 3 times a day (600 mg/day).
- The course of treatment is 5-7 days, but no more than 7 days. If during the first 3 days of treatment there is no improvement, you should consult a doctor.
